> Avacta committed to moving its tumor microenvironment activated drug conjugate into the clinic ahead of schedule. Testing in humans is due to start next year. Statement
> Themis Bioscience secured up to $21 million (€19 million) in non-dilutive funding to support a phase 3 trial of its Chikungunya vaccine. Filings to start the trial are planned for later this year. Release
> Merck KGaA published interim data from a phase 2 trial of tepotinib in non-small cell lung cancer. The trial linked the MET kinase inhibitor to a response rate of around 50%. Statement
> Sotio’s autologous immunotherapy achieved a 15.5 month overall survival in stage 4 non-small cell lung cancer, as compared to 11.8 months in the control arm. Release
> BerGenBio presented updated data from a trial of bemcentinib and low-intensity chemotherapy in elderly acute myeloid leukemia patients. About half of the subjects responded to the regimen. Statement
> Corbin Therapeutics licensed neuroinflammation assets from the University of Dundee Drug Discovery Unit. Release